High affinity fusion proteins and therapeutic and diagnostic methods for use
OwnerNeil Stahl, George Yancopoulos +2inventors
InventorsNeil Stahl, George Yancopoulos, Margaret Karow, Eric Smith
Life of this patent
Estimating the term…
Abstract
High affinity fusion proteins capable of binding and inhibiting the activity of soluble, interacting proteins (“SIPs”) are described. In specific embodiments the fusion proteins are multimers, preferably dimers, of SIP-specific fusion polypeptides which comprise SIP binding domains derived from SIP targets and/or anti-SIP immunoglobulin domains, as well as multimerizing components.
Claims29
An isolated nucleic acid encoding a SIP-specific fusion polypeptide, wherein the fusion polypeptide comprises:
- (a) one or more components which comprise a SIP binding domain of a SIP target (TBD);
- (b) one or more components which comprise a SIP binding domain of an immunoglobulin (IBD);
- and
- (c) a multimerizing component (M) capable of multimerizing with a multimerizing component on another fusion polypeptide to form a multimer of the fusion polypeptides.
An isolated nucleic acid encoding a SIP-specific fusion polypeptide, wherein the fusion polypeptide comprises:
- (a) two or more components which comprise a SIP binding domain of an immunoglobulin (IBD);
- and
- (b) a multimerizing (M) component.
An isolated nucleic acid encoding (i) a VL CDR selected from the group consisting of SEQ ID NOs:27-32, 43-48, 59-64, 75-80, 91-96 and 107-112, and (i) a VH CDR selected from the group consisting of SEQ ID NOs:19-24, 35-40, 51-56, 67-72, 83-88, and 99-104.
A trapbody, comprising two fusion polypeptides and capable of binding a soluble protein (SIP), wherein each fusion polypeptide comprises IBD′-IBD″-M, wherein IBD′ and IBD″ are specific to different epitopes of the same SIP, and the trapbody exhibits at least a five-fold increase in affinity relative to a dimer composed of two fusion polypeptides each having a single IBD and a multimerizing component.
A human IL-6-specific trapbody, comprising IBD-IBD-M, wherein each IBD comprise at least one CDR sequence selected from the group consisting of SEQ ID NOs:19-24, 27-32, 35-40, 43-48, 51-56, 59-64, 67-72, 75-80, 83-88, 91-96, 99-104 and 107-112.
An antibody heavy chain or heavy chain fragment, comprising one or more of CDR1, CDR2 and CDR3, wherein (i) CDR1 is selected from the group consisting of SEQ ID NO:19, 22, 35, 38, 51, 54, 67, 70, 83, 86, 99 and 102;
- (ii) CDR2 is selected from the group consisting of SEQ ID NO:
- 20, 23, 36, 39, 52, 55, 68, 71, 84, 87, 100 and 103;
- and (iii) CDR3 is selected from the group consisting of SEQ ID NO:
- 21, 24, 37, 40, 53, 56, 69, 72, 85, 88, 101 and 104.
An antibody light chain or light chain fragment, comprising one or more of CDR1, CDR2 and CDR3, wherein (i) CDR1 is selected from the group consisting of SEQ ID NO:
- 27, 30, 43, 46, 59, 62, 75, 78, 91, 94, 107 and 110;
- (ii) CDR2 is selected from the group consisting of SEQ ID NO:
- 28, 31, 44, 47, 60, 63, 76, 79, 92, 95, 108, and 111;
- and (iii) CDR3 is selected from the group consisting of SEQ ID NO:
- 29, 32, 45, 48, 61, 64, 77, 80, 93, 96, 109 and 112.
Dependencies are inferred from the claim text.